Clinical Trials Logo

Cerebral Aneurysm clinical trials

View clinical trials related to Cerebral Aneurysm.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02503553 Withdrawn - Cerebral Aneurysm Clinical Trials

Decision Aids in Cerebral Aneurysm Treatment

Start date: n/a
Phase: N/A
Study type: Interventional

Identifying and making a decision about the best health treatment or screening option can be difficult for patients. Decision aids can be used when there is more than one reasonable option, when no option has a clear advantage in terms of health outcomes, and when each option has benefits and harms that patients may value differently. Decision aids may be pamphlets, videos, or web-based tools. They make the decision explicit, describe the options available, and help people to understand these options as well as their possible benefits and harms. This helps patients to consider the options from a personal view (e.g., how important the possible benefits and harms are to them) and helps them to participate with their health practitioner in making a decision. Cerebral aneurysms are common and potentially very dangerous. However, there are important treatment choices that may prevent bleeding and stroke before aneurysm rupture.Current procedural options are clipping and endovascular coiling. The anatomy of most aneurysms is amenable to either treatment. The treatment decisions are not simple, since each choice has its own trade-offs. How the benefits and trade-offs are valued varies across different patients, and, therefore, the right treatment decision needs to include greater patient participation. This starts with better communication of the probabilities associated with the outcomes of each option in terms that can be understood by patients. Equally important is helping the patients clarify their own treatment goals, as well as legitimizing patients' partnership in the decision-making process. Tools (e.g., decision aids) to achieve shared decision-making, are lacking in this area of medicine. We propose to investigate the impact of such decision aids on patient satisfaction and the outcomes of cerebral aneurysm coiling and clipping. Aim 1. To determine whether structured decision aids offered to cerebral aneurysm patients are associated with increased patient participation in the decision making process as indicated by the OPTION score Aim 2. To determine whether structured decision aids offered to cerebral aneurysm patients are associated with improved quality of life and patient satisfaction outcomes immediately preoperatively, and 30 days postoperatively.

NCT ID: NCT02011321 Withdrawn - Clinical trials for Subarachnoid Hemorrhage

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

CLEVAS
Start date: March 2014
Phase: Phase 2
Study type: Interventional

Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm

NCT ID: NCT01895881 Withdrawn - Menopause Clinical Trials

Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial

EPPA
Start date: April 2013
Phase: Phase 2
Study type: Interventional

This study aims to determine if hormone replacement therapy, given during perimenopause may prevent the progression of saccular cerebral aneurysms.

NCT ID: NCT01878136 Withdrawn - Clinical trials for Subarachnoid Hemorrhage

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the hypothesis that the administration of intraventricular tPA reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.

NCT ID: NCT01457443 Withdrawn - Lung Disease Clinical Trials

Biomarker for Pompe Disease (BioPompe)

BioPompe
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)